ASLAN Pharmaceuticals Ltd

Overview

• IndustryPharmaceutical Preparations²
• HeadquartersSingapore, Singapore²
• Incorporated inCayman Islands⁴
• Business address83 Clemenceau Avenue, #12-03 Ue Square, Singapore, U0 239920⁴
• Filer categoryNon-accelerated filer⁴
• Legal formOther²
• LEI549300L9VD6FZWFBND47²
• StatusActive²
• LEI statusIssued and current²
• Registered addressP. O. Box 897, Windward 1, Regatta Office Park, West Bay Road, KY1-1103 Grand Cayman, Cayman Islands²
• Registered withGeneral Registry, 289175²

See how the biggest companies compare on our leaderboards

ASLAN Pharmaceuticals Pte. Ltd. was incorporated in Singapore in April 2010 and ASLAN Pharmaceuticals Limited was incorporated in the Cayman Islands in June 2014. Our ADSs were listed on The Nasdaq Global Market (Nasdaq) from May 2018 to September 2022. On September 29, 2022, we transferred to The Nasdaq Capital Market and continued trading under the same trading symbol “ASLN”.⁵ From its latest annual report

Corporate structure

ASLAN Pharmaceuticals Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ASLAN Pharmaceuticals Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerAlexandre M. Kaoukhov named Apr 26, 2023 to Mar 28, 2024¹¹
• Executive OfficerBen M. Goodger named Apr 26, 2023 to Mar 28, 2024¹¹
• Executive Officer, DirectorCarl Firth, Ph.D. named Apr 26, 2023 to Mar 28, 2024¹¹
• Executive OfficerKiran Asarpota named Apr 26, 2023 to Mar 28, 2024¹¹
• Executive OfficerStephen M. Doyle named Apr 26, 2023 to Mar 28, 2024¹¹
• DirectorAndrew Howden named Apr 26, 2023 to Mar 28, 2024¹¹
• DirectorKathleen M. Metters named Apr 26, 2023 to Mar 28, 2024¹¹
• DirectorNeil Graham, MBBS, M.D., MPH named Apr 26, 2023 to Mar 28, 2024¹¹
• DirectorRobert E. Hoffman named Apr 26, 2023 to Mar 28, 2024¹¹

Timeline

1. Jun 23, 2014Founded ASLAN Pharmaceuticals Ltd is founded²

Filings

91 filings to the SEC since October 2021: 3 annual reports, 16 large holders, 2 private raises, 70 other. The latest 20:

1. Nov 14, 2024SC 13G/A EDGAR
2. Nov 14, 2024SC 13G EDGAR
3. Aug 8, 2024SCHEDULE 13G/A EDGAR
4. Jul 17, 20246-K EDGAR
5. Jul 15, 20246-K EDGAR
6. Jun 21, 2024EFFECT EDGAR
7. Jun 18, 2024CORRESP EDGAR
8. Jun 14, 20246-K EDGAR
9. Jun 14, 2024UPLOAD EDGAR
10. Jun 12, 2024F-3 EDGAR
11. May 31, 20246-K EDGAR
12. May 9, 20246-K EDGAR
13. May 7, 20246-K EDGAR
14. Apr 22, 20246-K EDGAR
15. Apr 19, 20246-K EDGAR
16. Apr 12, 2024424B5 EDGAR
17. Apr 12, 20246-K EDGAR
18. Apr 12, 2024S-8 EDGAR
19. Apr 12, 202420-F EDGAR
20. Apr 12, 20246-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• K2 HealthVentures Equity Trust LLCSC 13G/A, 3 filings Mar 20, 2023 to Nov 14, 2024¹²
• Lind Global Fund II LPSC 13G, 2 filings Mar 19, 2024 to Nov 14, 2024¹³
• UBSSCHEDULE 13G/A, 2 filings Feb 6, 2024 to Aug 8, 2024¹⁴
• INTRACOASTAL CAPITAL, LLCSC 13G, 1 filing Mar 21, 2024¹⁵
• BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 2 filings Mar 6, 2023 to Feb 14, 2024¹⁶
• TANG CAPITAL PARTNERS LPSC 13G/A, 3 filings Feb 14, 2023 to Jan 2, 2024¹⁷
• RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023¹⁸
• TANG CAPITAL MANAGEMENT LLCSC 13G, 1 filing Apr 21, 2022¹⁹

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Mar 14, 2024Raised $5 million in a private offering of securities¹¹ Form D: 4 investors so far Form D
2. Feb 27, 2023Raised $20 million in a private offering of equity²⁰ Form D: $100 million offered in all Form D

SEC filer profile

How ASLAN Pharmaceuticals Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARASLAN Pharmaceuticals Ltd¹
• CIK0001722926
• Filer statusNon-accelerated filer¹
• Incorporated inCayman Islands¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address83 Clemenceau Avenue, #12-03 Ue Square, Singapore, U0 239920¹
• Phone65 6222 4235¹
• Shares outstanding402,116,835 as of Dec 31, 2022¹⁰
• On EDGAR sinceDec 20, 2017¹
• Filings217 in all: 6-K (106), 424B5 (11), CORRESP (10), UPLOAD (10), EFFECT (9), SC 13G (9), SC 13G/A (8), F-3 (7)¹
  All 30 form types

  20-F (6), CT ORDER (5), F-1/A (4), S-8 (4), DRS/A (3), 424B4 (2), 6-K/A (2), D (2), DRS (2), DRSLTR (2), F-1 (2), F-6 POS (2), F-6EF (2), 20-F/A (1), 25-NSE (1), 8-A12B (1), CERT (1), F-3/A (1), F-6 (1), FWP (1), RW (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (20-F) Apr 12, 2024